Abstract
The efficiency of human fibroblast interferon (IFN-β) and human leukocyte interferon (IFN-α) was evaluated in two children with recurrent laryngeal papillomatosis. Both children failed to respond to fibroblast interferon, however the laryngeal papillomatosis disappeared when leukocyte interferon was applied. Possible explanations for these findings are discussed.
Similar content being viewed by others
References
Interferon nomenclature (1980) Nature 286:110
Cantell K (1979) Why is interferon not in clinical use today? In: Gresser I (ed) Interferon 1979. Academic Press, New York, pp 1–28
Sundmacher R, Cantell K, Skoda R, Hallermann C, Neumann-Haefelin D (1978) Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis. Albrecht v Graefes Arch Klin Exp Ophthalmol 208:229–233
Haglund S, Lundquist PG, Cantell K, Strander H (in press) Interferon therapy in juvenile laryngeal papillomatosis. Arch Otolaryngol
Billiau A, DeSomer P, Edy VG, DeClerc QE, Heremans H (1979) Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans. Antimicrob Agents Chemother 16:56–63
Arnold W (1979) Tubular forms of Papova viruses in human laryngeal papilloma. Arch Otolaryngol 225:15–19
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Göbel, U., Arnold, W., Wahn, V. et al. Comparison of human fibroblast and leukocyte interferon in the treatment of severe laryngeal papillomatosis in children. Eur J Pediatr 137, 175–176 (1981). https://doi.org/10.1007/BF00441312
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00441312